4d Molecular Therapeutics Stock Performance
| FDMT Stock | USD 7.50 0.20 2.74% |
The firm owns a Beta (Systematic Risk) of 2.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, 4D Molecular will likely underperform. At this point, 4D Molecular Therapeutics has a negative expected return of -0.26%. Please make sure to confirm 4D Molecular's coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if 4D Molecular Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days 4D Molecular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in February 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 2.74 | Five Day Return 2.32 | Year To Date Return 2.46 | Ten Year Return (81.48) | All Time Return (81.48) |
1 | Disposition of 1635 shares by Bizily Scott of 4D Molecular at 10.17 subject to Rule 16b-3 | 10/16/2025 |
2 | How Much Upside is Left in 4D Molecular Therapeutics Wall Street Analysts Think 171.74 percent - Zacks Investment Research | 11/03/2025 |
3 | Disposition of 1635 shares by Bizily Scott of 4D Molecular at 10.59 subject to Rule 16b-3 | 11/17/2025 |
4 | Acquisition by John Milligan of 26791 shares of 4D Molecular at 25.15 subject to Rule 16b-3 | 11/19/2025 |
5 | 4DMT to Participate in 8th Annual Evercore Healthcare Conference | 11/20/2025 |
6 | How geopolitical tensions affect 4D Molecular Therapeutics Inc. stock - July 2025 Breakouts Verified Entry Point Signals - Newser | 12/04/2025 |
7 | Insider Trading | 12/09/2025 |
8 | 4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks | 12/10/2025 |
9 | Acquisition by Bizily Scott of 1332 shares of 4D Molecular at 6.49 subject to Rule 16b-3 | 12/15/2025 |
10 | Disposition of 1635 shares by Bizily Scott of 4D Molecular at 10.9 subject to Rule 16b-3 | 12/16/2025 |
11 | 4D Molecular Therapeutics Jury Still Out On CF Gene Therapy After Dense Data Drop - Seeking Alpha | 12/19/2025 |
12 | 4D Molecular Therapeutics, Inc.s institutional investors lost 20 percent over the past week but have profited from longer-term gains | 12/23/2025 |
13 | Can 4D Molecular Therapeutics Inc. stock double in next 5 years - 2025 Analyst Calls Daily Technical Stock Forecast Reports - ulpravda.ru | 01/08/2026 |
| Begin Period Cash Flow | 249.1 M | |
| Total Cashflows From Investing Activities | -302.4 M |
4D Molecular Relative Risk vs. Return Landscape
If you would invest 967.00 in 4D Molecular Therapeutics on October 12, 2025 and sell it today you would lose (217.00) from holding 4D Molecular Therapeutics or give up 22.44% of portfolio value over 90 days. 4D Molecular Therapeutics is currently does not generate positive expected returns and assumes 5.5346% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than FDMT, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
4D Molecular Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for 4D Molecular's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as 4D Molecular Therapeutics, and traders can use it to determine the average amount a 4D Molecular's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0462
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FDMT |
Based on monthly moving average 4D Molecular is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of 4D Molecular by adding 4D Molecular to a well-diversified portfolio.
4D Molecular Fundamentals Growth
FDMT Stock prices reflect investors' perceptions of the future prospects and financial health of 4D Molecular, and 4D Molecular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FDMT Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (655.39) % | ||||
| Current Valuation | 134.29 M | ||||
| Shares Outstanding | 57.14 M | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 3,476 X | ||||
| Revenue | 37 K | ||||
| Gross Profit | (177.96 M) | ||||
| EBITDA | (181.14 M) | ||||
| Net Income | (160.87 M) | ||||
| Cash And Equivalents | 241.09 M | ||||
| Cash Per Share | 7.45 X | ||||
| Total Debt | 24.61 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 17.20 X | ||||
| Book Value Per Share | 7.89 X | ||||
| Cash Flow From Operations | (134.59 M) | ||||
| Earnings Per Share | (3.75) X | ||||
| Market Capitalization | 417.09 M | ||||
| Total Asset | 560.38 M | ||||
| Retained Earnings | (576.2 M) | ||||
| Working Capital | 405.78 M | ||||
About 4D Molecular Performance
Assessing 4D Molecular's fundamental ratios provides investors with valuable insights into 4D Molecular's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the 4D Molecular is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (490.04) | (514.54) | |
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.36) | (0.34) |
Things to note about 4D Molecular Therapeutics performance evaluation
Checking the ongoing alerts about 4D Molecular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 4D Molecular Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 4D Molecular generated a negative expected return over the last 90 days | |
| 4D Molecular has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 37 K. Net Loss for the year was (160.87 M) with loss before overhead, payroll, taxes, and interest of (177.96 M). | |
| 4D Molecular Therapeutics currently holds about 241.09 M in cash with (134.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.45. | |
| 4D Molecular has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Can 4D Molecular Therapeutics Inc. stock double in next 5 years - 2025 Analyst Calls Daily Technical Stock Forecast Reports - ulpravda.ru |
- Analyzing 4D Molecular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 4D Molecular's stock is overvalued or undervalued compared to its peers.
- Examining 4D Molecular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 4D Molecular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of 4D Molecular's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 4D Molecular's stock. These opinions can provide insight into 4D Molecular's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.